Clinical trial NCT04885153 - References

Diabetes Mellitus — Effects of Oral Fenofibrate on Retinal Thickness and Macular Volume

Citation(s)

•   Förstermann U, Sessa WC
  Nitric oxide synthases: regulation and function. Eur Heart J. 2012 Apr;33(7):829-37, 837a-837d. doi: 10.1093/eurheartj/ehr304. Epub 2011 Sep 1. Review.
•   Gustavsson C, Agardh CD, Zetterqvist AV, Nilsson J, Agardh E, Gomez MF
  Vascular cellular adhesion molecule-1 (VCAM-1) expression in mice retinal vessels is affected by both hyperglycemia and hyperlipidemia. PLoS One. 2010 Sep 13;5(9):e12699. doi: 10.1371/journal.pone.0012699.
•   Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA
  Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004 Dec;56(4):549-80. Review.
•   Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d'Emden MC, Crimet DC, O'Connell RL, Colman PG; FIELD study investigators
  Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007 Nov 17;370(9600):1687-97. Epub 2007 Nov 7.
•   Koshy J, Koshy JM, Thomas S, Kaur G, Mathew T
  Should we start all patients with diabetic retinopathy on fenofibrates? Middle East Afr J Ophthalmol. 2013 Oct-Dec;20(4):309-14. doi: 10.4103/0974-9233.120012. Review.
•   Landmesser U, Hornig B, Drexler H
  Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions. Semin Thromb Hemost. 2000;26(5):529-37. Review.
•   Massin P, Peto T, Ansquer JC, Aubonnet P, MacuFEN Study Investigators FT
  Effects of fenofibric acid on diabetic macular edema: the MacuFen study. Ophthalmic Epidemiol. 2014 Oct;21(5):307-17. doi: 10.3109/09286586.2014.949783. Epub 2014 Aug 18.
•   Noonan JE, Jenkins AJ, Ma JX, Keech AC, Wang JJ, Lamoureux EL
  An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes. 2013 Dec;62(12):3968-75. doi: 10.2337/db13-0800. Review.
•   Saxena S, Khatri M, Nadri G, Ankita
  Pathogenic Mechanisms for Outer Retinal Layer Changes in Diabetic Retinopathy. Ann Diabetes Metab Disord Contr. 2017; 1:113.
•   Wright AD, Dodson PM
  Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies. Eye (Lond). 2011 Jul;25(7):843-9. doi: 10.1038/eye.2011.62. Epub 2011 Mar 25. Review.
•   Xu J, Zou MH
  Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation. 2009 Sep 29;120(13):1266-86. doi: 10.1161/CIRCULATIONAHA.108.835223. Review.
•   Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S, Hamman RF, Ikram MK, Kayama T, Klein BE, Klein R, Krishnaiah S, Mayurasakorn K, O'Hare JP, Orchard TJ, Porta M, Rema M, Roy MS, Sharma T, Shaw J, Taylor H, Tielsch JM, Varma R, Wang JJ, Wang N, West S, Xu L, Yasuda M, Zhang X, Mitchell P, Wong TY; Meta-Analysis for Eye Disease (META-EYE) Study Group
  Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012 Mar;35(3):556-64. doi: 10.2337/dc11-1909. Epub 2012 Feb 1. Review.

Effects of Oral Fenofibrate on Retinal Thickness and Macular Volume: Assessments on Retinal Endothelial Vascular Dysfunction, Inflammation, and Angiogenesis in Diabetic Retinopathy With Dyslipidemia

Details for clinical trial NCT04885153